Download the slide set

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Adherence and persistence
with medication regimens is highly
relevant to disease outcomes
• Adherence to a medication regimen is generally defined as the extent to which
patients take medications as prescribed by their health care provider.1
• Methods that can be used to confirm adherence to a medication regimen include:
monitoring of pill count, monitoring of prescription refill rate, and patient use of
“smart” pill bottles, but these are all indirect measures.
•
Nonpersistence with antihypertensive therapy is associated with an increased
risk of myocardial infarction and stroke.2
1. Osterberg L, Blasche T. N Engl J Med. 2005;353:487-497.
2. Breekveldt-Postma NS et al. Curr Med Res Opin. 2008;24:121-127.
Prescription of a single-pill combination is associated with improved
adherence rates compared with free-combination therapy
SPC
(ACE inhibitor + CCB)
(n=2839)
88%
P<0.0001
Free combination
(ACE inhibitior + CCB)
(n=3367)
69%
0%
20%
40%
60%
80%
Medication possession ratio (MPR)*
*Defined
as the total number of days of therapy for medication dispensed/365 days of study follow-up
ACE, angiotensin-converting enzyme; CCB, calcium channel blocker; SPC, single-pill combination
Gerbino PP, Shoheiber O. Am J Health System Pharm. 2007;64:1279-1283.
100%
A new device* approved by the FDA1 can be included in
antihypertensive pills to monitor the adherence to treatment
• The ingestible sensor is made entirely of ingredients found in food and is activated
upon ingestion to transmit a unique number which is captured by an external patch.
• The ingestible sensor does not require any battery or antenna; it is powered by the
contact with stomach fluids.
• The ingestible sensor can be embedded in a drug
product and can be used for directly confirming
medication adherence, as part of a networked
wellness system.
• The networked system has already been tested
in hypertension and heart failure populations.
Edible sensor attached directly to a tablet
* The Ingestion Event Marker (IEM), by Proteus Health.
1. FDA approves digestible microchips to be placed in pills. Medscape. August 3, 2012.